Article Text

Download PDFPDF

Epidermal growth factor receptor and bladder cancer
  1. A J Colquhoun,
  2. J K Mellon
  1. University Division of Urology, Leicester General Hospital, Gwendolen Road, Leicester, UK
  1. Correspondence to:
 Professor J K Mellon, Clinical Sciences Unit, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK;


Muscle-invasive bladder cancer is a disease which causes significant morbidity and mortality. The two main forms of treatment for this disease include radical cystectomy and radical radiotherapy, but five year survival after treatment remains low at 40%. Many clinical and molecular risk factors have been shown to be associated with poor prognosis. One such factor is the expression of epidermal growth factor receptor (EGFR), which is overexpressed by many epithelial tumours, including bladder cancers. There are several methods of inhibiting the activity of EGFR and it may be that use of an anti-EGFR therapy, in combination with more conventional treatment, provides a method of improving the prognosis for muscle-invasive bladder cancer.

  • epidermal growth factor receptor
  • bladder neoplasms
  • EGF, epidermal growth factor
  • EGFR, epidermal growth factor receptor
  • HB-EGF, heparin-binding EGF-like factor
  • TGF-α, transforming growth factor-alpha

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.